The stock of La Jolla Pharmaceutical Company (NASDAQ:LJPC) is a huge mover today! The stock decreased 2.73% or $0.48 during the last trading session, hitting $16.92. About 189,566 shares traded hands or 41.33% up from the average. La Jolla Pharmaceutical Company (NASDAQ:LJPC) has declined 23.68% since April 6, 2016 and is downtrending. It has underperformed by 25.64% the S&P500.
The move comes after 5 months negative chart setup for the $332.05 million company. It was reported on Nov, 8 by Barchart.com. We have $14.55 PT which if reached, will make NASDAQ:LJPC worth $46.49M less.
La Jolla Pharmaceutical Company (NASDAQ:LJPC) Ratings Coverage
Out of 3 analysts covering La Jolla Pharmaceutical Company (NASDAQ:LJPC), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. La Jolla Pharmaceutical Company has been the topic of 4 analyst reports since August 11, 2015 according to StockzIntelligence Inc. On Tuesday, May 24 the stock rating was initiated by Lake Street with “Buy”. The rating was initiated by Cowen & Co with “Outperform” on Tuesday, February 9. The company was maintained on Tuesday, September 8 by Chardan Capital Markets. The company was downgraded on Tuesday, August 11 by Zacks.
According to Zacks Investment Research, “LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases.”
Insitutional Activity: The institutional sentiment increased to 1.9 in 2016 Q2. Its up 0.56, from 1.34 in 2016Q1. The ratio increased, as 6 funds sold all La Jolla Pharmaceutical Company shares owned while 14 reduced positions. 10 funds bought stakes while 28 increased positions. They now own 15.94 million shares or 0.70% less from 16.05 million shares in 2016Q1.
Teachers Advsrs Inc has 0% invested in the company for 23,042 shares. Northern Trust holds 0% or 189,583 shares in its portfolio. Credit Suisse Ag has 0% invested in the company for 32,741 shares. Paw Corporation accumulated 0.92% or 50,000 shares. Advsr Asset Mngmt, a Colorado-based fund reported 46,476 shares. Granahan Ma last reported 0.12% of its portfolio in the stock. Swiss Bank & Trust holds 24,400 shares or 0% of its portfolio. Hollencrest Securities Limited Liability Company accumulated 0.05% or 22,092 shares. Moreover, Janus Capital Mgmt Ltd Liability has 0.02% invested in La Jolla Pharmaceutical Company (NASDAQ:LJPC) for 1.24 million shares. American Int Gp has 8,013 shares for 0% of their US portfolio. Wells Fargo & Mn last reported 18,160 shares in the company. Nationwide Fund Advisors holds 9,184 shares or 0% of its portfolio. Tower Research Cap Ltd (Trc) holds 2,306 shares or 0% of its portfolio. Susquehanna Interest Gru Ltd Liability Partnership holds 0% of its portfolio in La Jolla Pharmaceutical Company (NASDAQ:LJPC) for 13,123 shares. Jennison Assocs Lc, a New York-based fund reported 252,437 shares.
Insider Transactions: Since September 9, 2016, the stock had 1 insider purchase, and 0 selling transactions for $2.76 million net activity. TANG KEVIN C bought $2.76 million worth of La Jolla Pharmaceutical Company (NASDAQ:LJPC) on Friday, September 9.
More notable recent La Jolla Pharmaceutical Company (NASDAQ:LJPC) news were published by: Businesswire.com which released: “La Jolla Pharmaceutical Company Announces Financial Results for the Three and …” on November 03, 2016, also Medgadget.com with their article: “La Jolla Pharmaceutical Company Clinical Trial Review, Market Share, Strategy …” published on November 08, 2016, Businesswire.com published: “La Jolla Pharmaceutical Company Announces Agreement with European Medicines …” on September 07, 2016. More interesting news about La Jolla Pharmaceutical Company (NASDAQ:LJPC) were released by: Businesswire.com and their article: “La Jolla Pharmaceutical Company Announces First Quarter 2016 Financial Results …” published on May 06, 2016 as well as Businesswire.com‘s news article titled: “La Jolla Pharmaceutical Company Announces Proposed Underwritten Offering of …” with publication date: September 09, 2015.
LJPC Company Profile
La Jolla Pharmaceutical Company, incorporated on May 8, 2012, is a biopharmaceutical company. The Firm is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products. The Company’s product candidates in development include LJPC-501, LJPC-401, LJPC-30Sa and LJPC-30Sb.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.